Emavusertib
- Generic Name
- Emavusertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25N7O5
- CAS Number
- 1801344-14-8
- Unique Ingredient Identifier
- MH5DMF9JKY
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT06696768
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT06439836
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT05685602
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04278768
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
A Study of CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03328078
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Providence Saint John's Health Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.